Morgan Stanley downgraded Alkermes (NASDAQ: ALKS) from Overweight to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Downgrades

UBS Remains Sidelined on Alkermes plc (ALKS) Following Failed ALKS 5461 StudiesJanuary 22, 2016 9:40 AM Alkermes (ALKS) PT Cut to $58 at Leerink Partners; Maintains 'Outperform'January 21, 2016 10:07 AM Cowen Downgrades Alkermes (ALKS) to Market PerformJanuary 21, 2016 9:51 AM Alkermes' (ALKS) Two Phase 3 Studies of ALKS 5461 in MDD Failed to Meet Primary Efficacy EndpointJanuary 21, 2016 7:03 AM Alkermes Announces Topline Results of FORWARD-3 and FORWARD-4, Two Phase 3 Studies of ALKS 5461 in Major Depressive DisorderJanuary 21, 2016 7:00 AM